EGFR-targeted therapy

被引：91

作者：

Vecchione, Loredana ^{[1
,2
,4
]}

Jacob, Bart ^{[1
,2
]}

Normanno, Nicola ^{[3
]}

Ciardiello, Fortunato ^{[4
]}

Tejpar, Sabine ^{[1
,2
]}

机构：

[1] Univ Hosp Gasthuisberg, Digest Oncol Unit, BE-3000 Louvain, Belgium

[2] Katholieke Univ Leuven, Ctr Human Genet, BE-3000 Louvain, Belgium

[3] INT Fdn Pascale, Cell Biol & Biotherapy Unit, I-80131 Naples, Italy

[4] Univ Naples 2, Div Med Oncol, Dept Expt & Clin Med & Surg F Magrassi & A Lanzar, I-80131 Naples, Italy

来源：

EXPERIMENTAL CELL RESEARCH | 2011年 / 317卷 / 19期

关键词：

EGFR signaling; Oncogenic dependency; Colorectal cancer; Anti-EGFR inhibitors; Molecular subgroups; Personalized cancer therapy; METASTATIC COLORECTAL-CANCER; GROWTH-FACTOR RECEPTOR; CETUXIMAB PLUS IRINOTECAN; GENE COPY NUMBER; CELL LUNG-CANCER; CLINICAL-PRACTICE; KRAS; MUTATIONS; PANITUMUMAB; BRAF;

D O I：

10.1016/j.yexcr.2011.08.021

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Anti-Epidermal Growth Factor Receptor (EGFR) therapies have been recently developed for the treatment of multiple cancer types. At the time when they were introduced in clinical practice, there was little knowledge of the molecular bases of tumor sensitivity and resistance to these novel targeted compounds. By using the framework of anti-EGFR inhibitors as treatment for colorectal cancer patients, we will review the knowledge we have reached until now in improving the development of a personalized cancer therapy and we will try to indicate the future challenges this field will face in the future. (C) 2011 Elsevier Inc. All rights reserved.

引用

页码：2765 / 2771

页数：7

共 60 条

[1] Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].

Amado, Rafael G. ;

Wolf, Michael ;

Peeters, Marc ;

Van Cutsem, Eric ;

Siena, Salvatore ;

Freeman, Daniel J. ;

Juan, Todd ;

Sikorski, Robert ;

Suggs, Sid ;

Radinsky, Robert ;

Patterson, Scott D. ;

Chang, David D. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634

[2]

[Anonymous], CAT SOM MUT CANC

[3]

[Anonymous], J CLIN ONCOL

[4] Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer [J].

Artale, Salvatore ;

Sartore-Bianchi, Andrea ;

Veronese, Silvio Marco ;

Gambi, Valentina ;

Sarnataro, Carolina Silvia ;

Gambacorta, Marcello ;

Lauricella, Calogero ;

Siena, Salvatore .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (25) :4217-4219

[5] Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer [J].

Baker, J. B. ;

Dutta, D. ;

Watson, D. ;

Maddala, T. ;

Munneke, B. M. ;

Shak, S. ;

Rowinsky, E. K. ;

Xu, L-A ;

Harbison, C. T. ;

Clark, E. A. ;

Mauro, D. J. ;

Khambata-Ford, S. .

BRITISH JOURNAL OF CANCER, 2011, 104 (03) :488-495

[6] Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies [J].

Benvenuti, Silvia ;

Sartore-Bianchi, Andrea ;

Di Nicolantonio, Federica ;

Zanon, Carlo ;

Moroni, Mauro ;

Veronese, Silvio ;

Siena, Salvatore ;

Bardelli, Alberto .

CANCER RESEARCH, 2007, 67 (06) :2643-2648

[7] Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer [J].

Bokemeyer, Carsten ;

Bondarenko, Igor ;

Makhson, Anatoly ;

Hartmann, Joerg T. ;

Aparicio, Jorge ;

de Braud, Filippo ;

Donea, Serban ;

Ludwig, Heinz ;

Schuch, Gunter ;

Stroh, Christopher ;

Loos, Anja H. ;

Zubel, Angela ;

Koralewski, Piotr .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) :663-671

[8] PREVALENCE OF RAS GENE-MUTATIONS IN HUMAN COLORECTAL CANCERS [J].

BOS, JL ;

FEARON, ER ;

HAMILTON, SR ;

VERLAANDEVRIES, M ;

VANBOOM, JH ;

VANDEREB, AJ ;

VOGELSTEIN, B .

NATURE, 1987, 327 (6120) :293-297

[9] EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients [J].

Cappuzzo, F. ;

Finocchiaro, G. ;

Rossi, E. ;

Jaenne, P. A. ;

Carnaghi, C. ;

Calandri, C. ;

Bencardino, K. ;

Ligorio, C. ;

Ciardiello, F. ;

Pressiani, T. ;

Destro, A. ;

Roncalli, M. ;

Crino, L. ;

Franklin, W. A. ;

Santoro, A. ;

Varella-Garcia, M. .

ANNALS OF ONCOLOGY, 2008, 19 (04) :717-723

[10] Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry [J].

Chung, KY ;

Shia, J ;

Kemeny, NE ;

Shah, M ;

Schwartz, GK ;

Tse, A ;

Hamilton, A ;

Pan, D ;

Schrag, D ;

Schwartz, L ;

Klimstra, DS ;

Fridman, D ;

Kelsen, DP ;

Saltz, LB .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (09) :1803-1810

← 1 2 3 4 5 6 →